Pre-Open Stock Movers 05/28: (AMC) (ITRM) (YEXT) Higher; (PRVB) (HPQ) (BIG) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Put Buying Activity in Beyond Meat (BYND) Targets 10% Downside in Shares Through July -Susquehanna
June 1, 2021 2:10 PM EDTSusquehanna options strategist Alison Edwards notes put buying activity in Beyond Meat (NASDAQ: BYND), as an opening investor purchased 3500 Jul 120 Puts for $4.90. This investor opens downside exposure to/protection against a move below $120 (down 10%).
... MorePalantir (PLTR) Trades at High, Up 7.6%
May 28, 2021 9:57 AM EDTPalantir (NYSE: PLTR) Trades at High, Up 7.6%
Veeva Systems (VEEV) PT Raised to $350 at Guggenheim
May 28, 2021 9:53 AM EDTGuggenheim analyst Ken Wong raised the price target on Veeva Systems (NYSE: VEEV) to $350.00 (from $340.00) while maintaining a Buy rating following strong first quarter results.
The analyst commented, "We view the consistency of Veeva's quarterly execution to be every bit as, if... More
AMC Entertainment (AMC) Extends Gain, Up 35%
May 28, 2021 9:32 AM EDTAMC Entertainment (NYSE: AMC) Extends Gain, Up 35%
Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets Following FDA AdComm Vote
May 28, 2021 9:29 AM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Provention Bio Inc. (NASDAQ: PRVB) to $22.50 (from $35.00) while maintaining a Buy rating following the FDA Advisory Committee vote.
The analyst commented, "Provention Bio (Buy): Yesterday, the FDA Advisory Committee (EMDAC)... More
